

151642

David S. Alberts · Lisa M. Hess *Editors*

Fundamentals of Cancer Prevention

Second Edition

 Springer

1	Introduction to Cancer Prevention	1
	D.S. Alberts, L.M. Hess	
1.1	Summary of Changes to Second Edition	3
1.2	Overview of Cancer Prevention	4
1.2.1	Primary Prevention	5
1.2.2	Secondary Prevention	6
1.2.3	Tertiary Prevention	6
1.3	Multi-Step Carcinogenesis Pathway	7
1.4	Cancer Prevention Research	8
	References	11
2	Assessing Human and Economic Benefits of Cancer Prevention	13
	S.J. Coons, B.M. Craig	
2.1	Outcomes Assessment	13
2.2	Humanistic Outcomes	14
2.3	Measuring Health-Related Quality of Life and Other Patient-Reported Outcomes	15
2.3.1	Specific Measures	16
2.3.2	Generic or General Measures	18
2.4	Economic Outcomes and Cancer	20
2.5	Defining and Measuring Economic Outcomes	21
2.6	Evaluative and Descriptive Analyses in Cancer Prevention	23

2.7	Conclusion	26
	References	26
3	The Role of Diet, Physical Activity and Body Composition in Cancer Prevention	31
	C.A. Thomson, Z. Chen	
3.1	Introduction	31
3.2	Recommendations for Cancer Prevention: Body Weight, Diet, and Physical Activity	32
3.3	Diet and Cancer Prevention: Review of Evidence	33
3.4	Clearing the Muddied Waters: The Need for Improved Study Designs	36
3.5	Physical Activity and Cancer Prevention	38
3.6	Body Weight and Body Composition and Cancer Prevention	41
3.7	Lifestyle and Cancer Survivorship	43
3.8	Body Weight and Cancer Survival	44
3.9	Survivorship and Diet	45
3.10	Physical Activity and Cancer Survivorship	47
3.11	Optimizing Bone Health	49
3.12	Mechanisms of Carcinogenesis Modified by Lifestyle Factors	53
3.13	Biological Mechanisms by Which Physical Activity May Reduce Cancer Risk	58
3.14	Advancing the Guidelines for Cancer Preventive Lifestyle	60
3.15	Tools for Research and Clinical Practice	62
3.16	Measuring Diet	62
3.17	Assessment of Physical Activity and Energy Expenditure	64
3.18	Measurement of Body Composition	66
3.19	Measurement of Bone Health	68
3.20	Conclusion	69
	References	71
4	Innate and Adaptive Immune Responses to Cancer	79
	K.T. Hastings	
4.1	Importance of the Immune System in Cancer Prevention	79
4.2	Innate Immune Responses to Cancer	81
4.2.1	Natural Killer Cells	82
4.2.2	Gamma-Delta T Cells	83
4.2.3	Phagocytes	85
4.2.4	Cytokines	86
4.3	Adaptive Immune Response	89
4.3.1	Recognition of Tumor Antigens	89
4.3.2	Tumor Antigens	90

4.3.3	T Lymphocytes	95
4.3.4	B Lymphocytes	97
4.3.5	Cytokines	98
4.4	Immunotherapy for Cancer Prevention	101
	References	102
5	Hereditary Risk for Cancer	109
	K.S. Hunt, J.A. Ray	
5.1	Cancer as a Genetic Disorder	109
5.1.1	Molecular Genetics	109
5.1.2	Tumor Suppressor Genes.	110
5.1.3	Oncogenes	111
5.1.4	DNA Repair Genes	111
5.2	Epigenetic Mechanisms.	112
5.3	Cancer as a Hereditary Disease	112
5.4	Common Hereditary Cancer Syndromes.	114
5.4.1	Hereditary Breast and Ovarian Cancer	114
5.4.2	Cowden Syndrome.	116
5.4.3	Li Fraumeni Syndrome	117
5.4.4	CHEK2	117
5.4.5	Ataxia-Telangiectasis.	118
5.4.6	Hereditary Nonpolyposis Colorectal Cancer	118
5.4.7	Familial Adenomatous Polyposis	120
5.4.8	Attenuated Familial Adenomatous Polyposis	120
5.4.9	Peutz–Jeghers Syndrome	121
5.4.10	Hereditary Diffuse Gastric Cancer	121
5.5	Genetic Counseling	121
5.5.1	Cancer Risk Assessment Models	122
5.5.2	Epidemiologic Models of Breast Cancer Risk.	123
5.5.3	Genetic Testing Models	123
5.5.4	Informed Consent Prior to Genetic Testing.	124
5.6	Genetic Testing	125
5.6.1	Genetic Testing for Hereditary Breast and Ovarian Cancer	125
5.6.2	Genetic Testing for Hereditary Nonpolyposis Colon Cancer	126
5.6.3	Genetic Testing for Familial Adenomatous Polyposis	127
5.6.4	Genetic Testing for Attenuated FAP	127
5.7	Cancer Screening, Surveillance and Prophylactic Management for Hereditary Cancer Syndromes.	128
5.7.1	Prevention Strategies for Hereditary Breast/Ovarian Cancer	128
5.7.2	Prevention Strategies for Hereditary Colorectal Cancer Syndromes.	129
5.7.3	Prophylactic Surgery	130
5.7.4	Chemoprevention.	130
5.8	Conclusion	131
	References	131

6	Human Categories and Health: The Power of the Concept of Ethnicity	137
	K. Coe, C.T. Palmer	
6.1	Introduction	137
6.2	Background	138
6.3	Race and the Failure of Attempts to Define Ethnicity	139
6.4	The Interactive View of Human Development.	142
6.4.1	Biologic, Genetic and Environmental	142
6.4.2	Learned and Innate.	143
6.4.3	Heritability and Inheritable	143
6.4.4	Cultural.	144
6.4.5	Traditional	144
6.5	The Interactive View of Development and Health	145
6.6	Identifying Ethnicity Using Proxy Measures	149
6.7	Ethnicity and Health.	150
6.8	Applications to Disparity Research	152
6.9	Conclusion	154
	References	155
7	Complementary and Alternative Approaches to Cancer Prevention	159
	L.K. Larkey, H. Greenlee, L.E. Mehl-Madrona	
7.1	CAM and Cancer Prevention Research	160
7.2	Botanical Agents: Foods, Spices, and Herbs	161
7.2.1	Curcumin	162
7.2.2	Green Tea	163
7.2.3	Immune Modulating Mushrooms.	163
7.2.4	Ginseng	164
7.2.5	Flaxseed	165
7.3	The Mind–Body Connection	165
7.3.1	Coping and Immunity	166
7.3.2	Psychological States, Interventions, and Cancer	167
7.3.3	Wellness	169
7.4	Indigenous Cultural Systems of Healing	171
7.4.1	Ayurveda	172
7.4.2	Native American Healing Traditions	173
7.4.3	Energy Medicine	174
7.5	Conclusions	178
	References	180
8	Telemedicine in Cancer Prevention	191
	A.M. Lopez, L. Kreykes	
8.1	What is Telemedicine?	191
8.2	Telemedicine in Cancer Care	192
8.3	Primary Cancer Prevention	193

8.3.1	Smoking Prevention	193
8.3.2	Nutrition Counseling	193
8.3.3	Exercise Education	194
8.3.4	Genetic Counseling	195
8.3.5	Psychosocial Support	196
8.4	Secondary Prevention.	196
8.4.1	Breast Cancer	196
8.4.2	Cervical Cancer	197
8.4.3	Skin Cancer	198
8.4.4	Colorectal Cancer.	199
8.4.5	Prostate Cancer.	200
8.4.6	Telepathology	201
8.5	Educating the Community Health Worker	201
8.6	Future Directions	202
	References	202
9	The Drug Development Process	205
	N.E. McKenzie	
9.1	Selecting New Molecular Entities for Development as Chemopreventive Agents	206
9.2	Regulatory Requirements and the US Food and Drug Administration	207
9.3	The Investigational New Drug Application	208
9.4	Phases of Clinical Research.	210
9.5	Good Clinical Practice	211
9.6	The New Drug Application	212
9.7	Conclusion	212
	References	213
10	Developing Topical Prodrugs for Skin Cancer Prevention	215
	E.L. Jacobson, H. Kim, M. Kim, G.T. Wondrak, M.K. Jacobson	
10.1	Strategies for Intervention	216
10.2	Strategy 1: Preventing DNA Damage	217
10.3	Strategy 2: Enhancing DNA Repair.	221
10.4	Strategy 3: Preventing Photoimmune Suppression	222
10.5	Strategy 4: Enhancing the Epidermal Barrier	223
10.6	Innovative Agents for Skin Cancer Prevention are Needed	224
10.7	Topical Delivery: The Cornerstone of a Skin Damage Prevention Strategy	225
10.8	Developing a Niacin Prodrug as a Potential Skin Cancer Prevention Agent	228
10.9	Clinical Development of Tetradecyl Nicotinate (Nia-114)	231
10.10	Summary	233
	References	234

11	Skin Cancer Prevention	239
	M. Lloria-Prevatt, D.S. Alberts	
11.1	Epidemiology of Skin Cancer	239
11.2	Risk Factors	241
11.2.1	Ultraviolet Radiation Exposure	241
11.2.2	Other Risk Factors	242
11.2.3	Genetic Alterations in NMSC	243
11.2.4	Genetic Alterations in Melanoma	244
11.3	Screening and Early Detection	245
11.4	Prevention of Skin Cancer	246
11.4.1	Primary Prevention	246
11.4.2	Secondary Prevention	248
11.4.3	Targeting Precursor Lesions for Chemoprevention	249
11.4.4	Molecular Targets for Chemoprevention Identified in UVR Signaling Pathways	251
11.4.5	Animal Models for Studying Chemoprevention Agents	257
11.4.6	Endpoints for Evaluating Efficacy of Chemoprevention Agents	258
11.4.7	Potential Chemoprevention Agents for Skin Cancer	262
11.5	Conclusion	274
	References	275
12	Colorectal Cancer Prevention	291
	A. Ismail, E. Gerner, P. Lance	
12.1	Epidemiology	292
12.2	Risk Factors	293
12.2.1	Physical Activity	293
12.2.2	Family History of Colorectal Adenoma or Colorectal Carcinoma	293
12.2.3	Inflammatory Bowel Disease	294
12.2.4	Other Risk Factors	294
12.3	Screening and Early Detection	295
12.3.1	Fecal Occult Blood Test (FOBT)	296
12.3.2	Flexible Sigmoidoscopy	297
12.3.3	Barium Enema	299
12.3.4	Colonoscopy	299
12.3.5	History of CRAs or CRC	300
12.3.6	Inflammatory Bowel Disease	300
12.3.7	FAP and HNPCC Kindreds	301
12.3.8	First-Degree Relatives of People with CRAs or CRCs	301
12.3.9	Emerging Screening Tests	301
12.3.9.1	Fecal DNA	301
12.3.9.2	Virtual Colonoscopy	302
12.4	Chemoprevention	303

12.4.1	Fiber	303
12.4.2	Folate.	304
12.4.3	Polymorphisms are Alternative Alleles of a Gene	304
12.4.4	Calcium.	305
12.4.5	Selenium	305
12.4.6	Aspirin and Non-Steroidal Anti-Inflammatory Drugs	305
12.4.7	Ursodeoxycholic Acid.	306
12.4.8	Current Status of CRC Chemoprevention.	307
	References.	308
13	Lung Cancer Prevention	313
	I. Hakim, L. Garland	
13.1	The Epidemiology of Lung Cancer	313
13.1.2	Trends in Tobacco Use in the United States.	313
13.1.3	The Narrowing of the Gender Gap in Smoking Prevalence.	314
13.1.4	Demographic Variables and Tobacco Use	315
13.2	Etiology of Lung Carcinogenesis.	317
13.2.1	Oxidative Damage	317
13.3	Cell Proliferation and Lung Carcinogenesis	319
13.4	Apoptosis and Lung Carcinogenesis	320
13.5	Genetic Factors in Carcinogen Metabolism.	320
13.6	DNA Hypermethylation and Lung Carcinogenesis	321
13.7	Risk Factors for Lung Cancer	322
13.7.1	Tobacco Products.	322
13.7.2	Environmental Exposures	324
13.7.3	Family History	325
13.7.4	Genetic Susceptibility	326
13.8	Screening for Early Detection	327
13.8.1	Preneoplasia and Intraepithelial Neoplasia	327
13.8.2	Standard Chest X-Rays and Sputum Cytology	328
13.8.3	Helical Computed Tomography	328
13.8.4	National Early Detection Initiatives.	329
13.9	Chemoprevention.	330
13.9.1	Chemopreventive Agents Under Investigation.	330
13.9.2	Dietary Supplements	332
13.9.3	Selenium.	333
13.9.4	Tea and Derivatives	335
13.10	Conclusion	336
	References	337
14	Breast Cancer Prevention	347
	P.A. Thompson, A.T. Stopeck	
14.1	Introduction.	347
14.2	Etiology.	348

14.3	Changing Patterns of Breast Cancer Incidence	348
14.4	Established Breast Cancer Risk Factors	351
14.4.1	Age, Gender and Breast Cancer Risk	352
14.4.2	Family History of Breast Cancer	353
14.4.3	Reproductive Risk Factors	355
14.4.4	Endogenous Hormone Exposures	356
14.4.5	Exogenous Hormone Exposures	357
14.5	Prior Breast Health History	359
14.6	Lifestyle Risk Factors	361
14.7	Risk Factors and Tumor Subtypes	361
14.8	Emerging Breast Cancer Risk Factors for Patient Management	362
14.9	Environmental Risk Factors	363
14.10	Screening and Early Detection	363
14.11	Breast Self Exam (BSE) and Clinical Breast Exam (CBE)	364
14.12	Mammography	364
14.13	Alternative Screening Modalities and Future Directions	365
14.14	Primary Prevention of Breast Cancer	366
14.15	Chemoprevention	367
14.15.1	Selective Estrogen Receptor Modulators (Serms)	367
14.15.2	Aromatase Inhibitors	368
14.15.3	Retinoids	371
14.15.4	Non-Steroidal Anti-Inflammatory Drugs (Nsaids)	371
14.15.5	Other Agents	372
14.16	Risk Assessment and Clinical Applications	372
14.16.1	Elevated Risk	372
14.16.2	Risk Assessment Models	373
14.17	Conclusion	375
	References	376
15	Prostate Cancer Prevention	387
	S. Stratton, F. Ahmann	
15.1	Prevention of Prostate Carcinogenesis	387
15.2	Epidemiology and Risk Factors	389
15.3	Risk Factors	390
15.4	Screening	393
15.5	Molecular Markers of Prostate Carcinogenesis	394
15.6	Prevention Strategies	401
15.6.1	Androgen Inhibitors	401
15.6.2	Selenium and Vitamin E	402
15.6.3	Soy Isoflavones	405
15.6.4	Cox-2 Inhibitors	407
15.6.5	Milk Thistle	408
15.6.6	Saw Palmetto	409
15.6.7	Resveratrol	410

15.7	Conclusion	410
	References	413
16	Cervical Cancer Prevention	423
	F. Garcia, T. Nuno, A.L. Mitchell	
16.1	Incidence and Mortality of Cervical Cancer	423
16.2	Etiology of Cervical Cancer	424
16.3	Natural History of Cervical Cancer	425
16.4	Co-Factors for Cervical Cancer	427
16.5	Viral Persistence	428
16.6	Screening and Early Detection of Cervical Cancer	429
16.6.1	Cytologic Screening	429
16.6.2	HPV Testing	431
16.7	Therapeutic Approach to Precursor Lesions of Cervical Cancer	432
16.8	Novel Agents for Cervical Cancer Prevention	433
16.8.1	Chemopreventive Agents	433
16.8.2	Therapeutic Vaccines	434
16.8.3	HPV Prophylactic Vaccines	435
16.9	Conclusion	438
	References	438
17	Ovarian Cancer Prevention	447
	S.K. Chambers, L.M. Hess	
17.1	Epidemiology	447
17.2	Histopathology	449
17.3	Risk Factors for Epithelial Ovarian Cancer	450
17.4	Early Detection and Prevention of Ovarian Cancer	457
17.5	Chemoprevention of Ovarian Cancer	462
17.6	Quality of Life	463
17.7	Conclusion	467
	References	467
18	Endometrial Cancer Prevention	475
	F. Garcia, S.K. Chambers	
18.1	Epidemiology of Endometrial Cancer	475
18.2	Types of Endometrial Cancer	476
18.3	Risk Factors for Endometrial Cancer	478
18.4	Genetic Factors in Endometrial Cancer	483
18.5	Screening and Early Detection of Endometrial Cancer	486
18.6	Conclusion	488
	References	488

19 Cancer Survivorship	495
R. Krouse, N.M. Aziz	
19.1 Prevalence.....	496
19.2 Survivorship as a Scientific Discipline.....	498
19.3 Prevention.....	498
19.4 Smoking Cessation.....	499
19.5 Acute Effects of Treatment.....	500
19.5.1 Chemotherapy.....	500
19.5.2 Surgery.....	502
19.5.3 Radiation Therapy.....	502
19.6 Long-Term and Late Effects of Cancer Treatment.....	503
19.7 Generalizations.....	505
19.8 Physiologic Sequelae of Cancer and Its Treatment.....	507
19.9 Advanced Illness.....	514
19.10 Future Directions.....	515
References.....	520
Index	529